Vivani Medical (NASDAQ:VANI) Stock: Insider Gregg Williams Acquires 48,100 Shares

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams acquired 48,100 shares of Vivani Medical stock in a transaction dated Friday, November 13th. The stock was acquired at an average cost of $0.99 per share, with a total value of $47,619.00. Following the completion of the transaction, the director directly owned 36,960,836 shares of the company’s stock, valued at $36,591,227.64. This trade represents a 0.13% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vivani Medical Trading Up 2.9%

Shares of VANI stock opened at $1.05 on Wednesday. Vivani Medical, Inc. has a 1 year low of $0.80 and a 1 year high of $1.66. The firm’s fifty day simple moving average is $1.17 and its 200 day simple moving average is $1.24. The firm has a market capitalization of $94.71 million, a P/E ratio of -3.28 and a beta of 2.51.

Vivani Medical (NASDAQ:VANI – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, October 2nd. Wall Street Zen lowered Vivani Medical from a “hold” rating to a “sell” rating in a research note on Sunday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Get Our Latest Analysis on VANI

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

Read More

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.